低剂量健择同步高-低氧放射治疗局部晚期胰腺癌的临床价值  

Value of low doses of gemcitabine chemotherapy combined with high-low oxygen radiotherapy synchronously for therapy of patients with locally advanced pancreatic cancer

作　　者：丁兆军[1] 孙衍伟[1] 陈希平[1] 安永恒[2] 

机构地区：[1]日照市人民医院肿瘤科,山东省日照市276826 [2]青岛大学医学院附属医院肿瘤治疗中心

出　　处：《中华胰腺病杂志》2012年第3期153-155,共3页Chinese Journal of Pancreatology

摘　　要：目的评价低剂量健择同步高一低氧放射治疗局部晚期胰腺癌的临床疗效及不良反应。方法将56例局部晚期胰腺癌患者按信封法随机分为放化疗组和化疗组。放化疗组采用低剂量健择（600mg／m^2）同步高一低氧放射治疗，化疗组采用足量健择（1000mg／m^2）化疗，观察两组的近期疗效、远处转移率、临床获益率、生存率及不良反应。结果放化疗组完全缓解1例，部分缓解15例，总有效率66．7％（16／24），化疗组部分缓解9例，总有效率36．0％（9／25），两组差异具有统计学意义（Х^2=4．6082，P=0．0318）；两组临床获益率分别为83．3％（20／24）和60．0％（15／25），差异无统计学意义（P=0．0707）；远处转移率分别为66．7％（16／24）和72．0％（18／25），差异无统计学意义（P=0．6855）；两组12、24个月生存率分别为62．5％和32．0％、37．5％和12．0％，差异均具有统计学意义（P值分别为0．0325、0．0380）；严重不良反应发生率分别为45．8％和40．0％，差异无统计学意义（P=0．6800）。结论低剂量健择同步高一低氧放射治疗局部晚期胰腺癌在总有效率及12、24个月生存率方面优于足量健择化疗，不良反应无明显增加。Objective To evaluate the efficacy and adverse effects of low doses gemeitabine chemotherapy combined with synchronous high-low oxygen radiotherapy in patients with locally advanced pancreatic cancer. Methods Fifty-six patients with locally advanced pancreatic cancer were randomly divided into two groups by envelop method： radio-chemotherapy group or chemotherapy group. Patients in radioehmotherapy group were treated with low doses of gemcitabine chemotherapy （ 600 mg/m^2 ） combined with high-low oxygen radiotherapy synchronously, patents in ehmotherapy group were treated with full doses of gemeitabine chemotherapy （ 1000 mg/m^2 ）. The short-term effect, distant metastasis rate, clinical benefit rate, survival rate and adverse events of two groups were observed. Results There was one patient achieved complete relief and 15 patients achieved partial relief in radio-chemotherapy group with an overall effective rate of 66.7% （ 16/24 ） ; there were 9 patients achieved partial relief in chemotherapy group with an overall effective rate of 36.0% （9/25）, the difference between the two groups was statistically significaltt （X2 =4. 6082, P = 0.0318 ）. The clinical benefit rates were 83.3 % （ 20/24 ） and 60% （ 15/25 ） , respectively, the difference between the two groups was not statistically significant （P = 0. 070）. The distant metastasis rates were 66.7 % （16/24） and 72% （18/25）, respectively, the difference between the two groups was not statistically significant （P =0.6855）. The 12, 24 months survival rates were 62.5% vs 32%, 37.5% vs 12%, the difference between the two groups was statistically significant （P = 0. 0325, 0. 0380）. The incidence of serious adverse events was 45.8% and 4 0 % without statistical difference . Conclusions Low doses of gemcitabine chemotherapy combined with high-low oxygen radiotherapy synchronously is better than full doses of gemcitabine chemotherapy with regard to total effective rates and 12, 24 months survival rates, with no obvious incr

关 键 词：胰腺肿瘤 放射疗法 药物疗法 氧 吉西他滨 

分 类 号：R735.9[医药卫生—肿瘤]